Biotech production quadrupled for actives company
Silab is commissioning a new production line for unicellular organisms on its single site, within its Biotechnologies Production Unit, opened in 2015, providing a second production line for the large-scale culture of yeast, microalgae and bacteria.
Fully independent, it integrates a 15,000 L principal bioreactor, giving the company the means to quadruple the annual production of these high added-value, natural raw materials used to manufacture its active ingredients.
These microorganisms represent a powerful lever of innovation, as Brigitte Closs-Gonthier, Silab Deputy general manager for innovation, states: “They have immense potential, due to their diversity and their incredible metabolism. With this new line, Silab now has the means to further diversify its production of microorganisms and master their fascinating properties, opening up access to some unique molecules of interest.”
The integrated manufacture of unicellular organisms is also a key strategic area of focus, in line with the company’s strongly proclaimed value of independence, as Xavier Gaillard, Deputy general manager for strategy, explains: “This 5 million euro capacity investment is part of a wider 30 million euro investment program, which has been implemented over three years. This program stems from our desire to offer the cosmetic and dermo-cosmetic markets ever more innovative solutions, while responding to the current major challenges of security, traceability and sustainability of sourcing.”